Danicopan
- Generic Name
- Danicopan
- Brand Names
- Voydeya
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23BrFN7O3
- CAS Number
- 1903768-17-1
- Unique Ingredient Identifier
- JM8C1SFX0U
- Background
Danicopan is under investigation in clinical trial NCT03459443 (A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)).
Study of a Single Dose of Danicopan in Healthy Participants
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04889677
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
Study of Multiple Doses of Danicopan in Healthy Participants
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04889690
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
A Drug Interaction Study of Danicopan
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04709094
- Locations
- 🇺🇸
Clinical Study Site, Tempe, Arizona, United States
A Study of the Effects of Food and Age on Danicopan
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04551599
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT04469465
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study of Danicopan in Participants of Japanese Descent
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04451434
- Locations
- 🇦🇺
Clinical Study Site, Brisbane, Australia
Study of Danicopan in Participants With Hepatic Impairment
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03555539
- Locations
- 🇺🇸
Clinical Trial Site, Orlando, Florida, United States
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03472885
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
- Conditions
- C3 GlomerulopathyImmune Complex Membranoproliferative GlomerulonephritisIC-MPGNC3 GlomerulonephritisDense Deposit Disease
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03459443
- Locations
- 🇳🇱
Clinical Study Site, Nijmegen, Netherlands
A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03384186
- Locations
- 🇬🇧
Clinical Trial Site, Ruddington, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.